These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 21366417)
1. Development of new vaccines and drugs for TB: limitations and potential strategic errors. Orme IM Future Microbiol; 2011 Feb; 6(2):161-77. PubMed ID: 21366417 [TBL] [Abstract][Full Text] [Related]
2. Current and novel approaches to vaccine development against tuberculosis. Cayabyab MJ; Macovei L; Campos-Neto A Front Cell Infect Microbiol; 2012; 2():154. PubMed ID: 23230563 [TBL] [Abstract][Full Text] [Related]
3. Animal Models of Tuberculosis: An Overview. Williams A; Orme IM Microbiol Spectr; 2016 Aug; 4(4):. PubMed ID: 27726810 [TBL] [Abstract][Full Text] [Related]
4. Tuberculosis in Africa: learning from pathogenesis for biomarker identification. Kaufmann SH; Parida SK Cell Host Microbe; 2008 Sep; 4(3):219-28. PubMed ID: 18779048 [TBL] [Abstract][Full Text] [Related]
6. The current state of tuberculosis vaccines. Hokey DA; Ginsberg A Hum Vaccin Immunother; 2013 Oct; 9(10):2142-6. PubMed ID: 23792698 [TBL] [Abstract][Full Text] [Related]
7. Towards new TB vaccines: What are the challenges? Dockrell HM Pathog Dis; 2016 Jun; 74(4):ftw016. PubMed ID: 26960944 [TBL] [Abstract][Full Text] [Related]
8. Overcoming the global crisis: "yes, we can", but also for TB ... ? Ottenhoff TH Eur J Immunol; 2009 Aug; 39(8):2014-20. PubMed ID: 19672895 [TBL] [Abstract][Full Text] [Related]
10. Achieving STOP TB Partnership goals: perspectives on development of new diagnostics, drugs and vaccines for tuberculosis. Mwaba P; McNerney R; Grobusch MP; O'Grady J; Bates M; Kapata N; Maeurer M; Zumla A Trop Med Int Health; 2011 Jul; 16(7):819-27. PubMed ID: 21489070 [TBL] [Abstract][Full Text] [Related]
11. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio. Palomino JC; Martin A Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617 [TBL] [Abstract][Full Text] [Related]
12. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development. Dietrich J; Doherty TM APMIS; 2009 May; 117(5-6):440-57. PubMed ID: 19400867 [TBL] [Abstract][Full Text] [Related]
13. Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine. Fu H; Lewnard JA; Frost I; Laxminarayan R; Arinaminpathy N Nat Commun; 2021 Jan; 12(1):424. PubMed ID: 33462224 [TBL] [Abstract][Full Text] [Related]
14. Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials. Ahsan MJ; Ansari MY; Yasmin S; Jadav SS; Kumar P; Garg SK; Aseri A; Khalilullah H Infect Disord Drug Targets; 2015; 15(1):32-41. PubMed ID: 25246035 [TBL] [Abstract][Full Text] [Related]
16. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. Lin MY; Ottenhoff TH Biol Chem; 2008 May; 389(5):497-511. PubMed ID: 18953716 [TBL] [Abstract][Full Text] [Related]
17. Strategies for developing tuberculosis vaccines: emerging approaches. Mollica A; Stefanucci A; Costante R Curr Drug Targets; 2013 Aug; 14(9):938-51. PubMed ID: 23469877 [TBL] [Abstract][Full Text] [Related]